<!DOCTYPE html>
<html lang="en" dir="ltr">
  <head>

    <title>Alzarrok: A Drug to Remember -Homepage</title>
    <link href="alzarrokotheroption.css" rel="stylesheet">
    
  </head>


  <body>

    <header>
      <div class="logo-container">
          <img src="https://64.media.tumblr.com/ea933195e7072aff55d7936ac8f480b9/b4834aec1938f367-e3/s540x810/6a0665085e9cc3d07ab7182c4ef5c517a8587529.pnj" alt="Logo" id="logo">
      </div>
      <nav class="navbar">
          <a href="#home" class="nav-item">Home</a>
          <a href="#about" class="nav-item">About</a>
          <a href="#contact" class="nav-item">Contact</a>
      </nav>
  </header>






<main>
<section>
  <!-- <div class="intro"><img src="https://64.media.tumblr.com/ab93f18732c4f2ec22d67286f17a6a45/61e542f7c8d0e06e-7b/s540x810/e76e225cf3bcd5a2d7beedbfffb46fb4e1bc5270.pnj"></div> -->
  <div class="opener">
    <h1 class="header" id="openheader">A Drug to Remember</h1>
        <p class="openertext">
        The primary focus of ALZARROK is the 
        development of a highly promising peptide drug, ALZ100,
        complemented by a superior delivery system, 
        with the goal of halting the decline in cognitive 
        function associated with Alzheimer’s disease.
        ALZARROK's patent-pending, multi-targeted 
        peptide offers an efficient and synergistic 
        approach to inhibit both neuroinflammation 
        and neurodegeneration. This therapeutic 
        peptide is being specifically designed for 
        intranasal delivery, which is expected to provide 
        two significant advantages over intravenous 
        administration: first, it will enhance targeting 
        efficiency and minimize degradation, and 
        second, it will allow for convenient self-administration by
        patient.
     </p>
  
  </div>
</section>

<div class = "infoparent">
<section class="info">
  <div class="company">
   <!-- <h2 class="hcompany">The Company</h2>  -->
      <p class="text">
        <br>
      </p>
      <img src="./images/thecompany.jpeg" alt="company about" class="boximages">
      
  </div>
</section>

<section class="info">
  <div class="inovative">
   <!--  <h2 class="hinovative">Innovative Advantages of AZ100</h2> -->
      <p class="text">
       <br>
      </p>
      <img src="./images/theinovation.jpeg" alt="Chart Displaying Insersion Method of Alzarrok" class="boximages">
  </div>
</section>


<section class="info">
  <div class="science">
    <!-- <h2 class="hscience">The Science</h2> -->
      
      <img src="./images/thesciencecorrect.jpeg" alt="Chart Displaying The Science Behind AZ100" class="boximages">
      <p class="text">
        Relevant Publications: <br>

    1. Kasus-Jacobi A, Washburn JL, Laurence RB, Pereira HA. Selecting Multitarget Peptides for Alzheimer's Disease. Biomolecules. 2022 Sep 27;12(10):1386. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36291595/">36291595</a><br>; PMCID: PMC9599826 <br>

    2. Kasus-Jacobi, A., Washburn, J., Land, C., Pereira, A. (2021). Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and Neurotoxicity. Curr Alzheimer Res, 18(5), 414-427. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34429047/">34429047</a><br>; PMCID: PMC979194<br>

    3. Kasus-Jacobi A., Land C.A., Stock A.J., Washburn J.L. and Pereira H.A. (2020) Antimicrobial peptides derived from the immune defense protein CAP37 inhibit TLR4 activation by S100A9. Invest Ophthalmol Vis Sci. Apr 9;61(4):16. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32298435/">32298435</a><br>; PMCID: PMC7401491<br>

    4. Stock A.J., Kasus-Jacobi A. and Pereira H.A. (2018). The role of neutrophil granule proteins in neuroinflammation and Alzheimer's disease. J Neuroinflammation, 15(1):240. Review. PMID: 30149799; PMCID: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112130/">PMC6112130</a><br>

    5. Stock AJ, Kasus-Jacobi A, Wren JD, Sjoelund VH, Prestwich GD, Pereira HA. The Role of Neutrophil Proteins on the Amyloid Beta-RAGE Axis. PLoS One. 2016 Sep 27;11(9):e0163330. PMID: 27676391; PMCID: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038948/">PMC5038948</a>

    6. Brock AJ, Kasus-Jacobi A, Lerner M, Logan S, Adesina AM, Anne Pereira H. The antimicrobial protein, CAP37, is upregulated in pyramidal neurons during Alzheimer's disease. Histochem Cell Biol. 2015 Oct;144(4):293-308. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26170148/">26170148</a><br>; PMCID: PMC457539
       </p>
  </div>
</section>
<!-- add links -->

<section class="info">
  <div class="funds">
    <!-- <h2 class="hfunds">Funding</h2> -->
      <p class="text">
       <br>
      </p>
      <img src="./images/thefunding.jpeg" alt="Funding Information" class="boximages">
  </div>
</section>
</div>


<section class="Team">
<div class="abtteam">
  <h2>The Team</h2> <br>
<img src="./images/theteam.jpeg" class="teamimage" alt="The Team">
</div>
</section>




<footer>
  <div class="finfo">
    <h2 class="publications">Publications</h2>
      <p class="text">
        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599826/pdf/biomolecules-12-01386.pdf">Selecting Multitarget Peptides for Alzheimer’s Disease
        </a>
      <br>

        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791948/pdf/nihms-1856543.pdf">Neutrophil Granule Proteins Inhibit Amyloid Beta Aggregation and Neurotoxicity
          </a>
        <br>
        
        <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112130/pdf/12974_2018_Article_1284.pdf">The role of neutrophil granule proteins in
          neuroinflammation and Alzheimer’s disease </a>
      </p>
  </div>
</footer>



    
      <!--Add your code below-->
      
      
   </main>
  </body>
</html>